Chemoradiotherapy, Adjuvant

"Chemoradiotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.

Descriptor ID	D059186
MeSH Number(s)	E02.186.079.500 E02.319.164.500 E02.815.160.500
Concept/Terms	Chemoradiotherapy, Adjuvant Chemoradiotherapy, Adjuvant Adjuvant Chemoradiotherapies Chemoradiotherapies, Adjuvant Adjuvant Radiochemotherapy Adjuvant Radiochemotherapies Radiochemotherapies, Adjuvant Radiochemotherapy, Adjuvant Adjuvant Chemoradiotherapy

Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy, Adjuvant".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Chemoradiotherapy [E02.186.079]
Chemoradiotherapy, Adjuvant [E02.186.079.500]
Drug Therapy [E02.319]
Chemoradiotherapy [E02.319.164]
Chemoradiotherapy, Adjuvant [E02.319.164.500]
Radiotherapy [E02.815]
Chemoradiotherapy [E02.815.160]
Chemoradiotherapy, Adjuvant [E02.815.160.500]

Below are MeSH descriptors whose meaning is related to "Chemoradiotherapy, Adjuvant".

Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy, Adjuvant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chemoradiotherapy, Adjuvant" by people in this website by year, and whether "Chemoradiotherapy, Adjuvant" was a major or minor topic of these publications.

Bar chart showing 37 publications over 12 distinct years, with a maximum of 6 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	1	0	1
2011	1	1	2
2012	2	2	4
2013	1	5	6
2014	2	1	3
2015	2	0	2
2017	3	2	5
2018	0	1	1
2019	2	3	5
2020	0	3	3
2021	0	4	4
2024	0	1	1

Below are the most recent publications written about "Chemoradiotherapy, Adjuvant" by people in Profiles.

Nadeem MS, Ali U, Khan A, Wajid I, Riaz O, Azeem MT. Response of various histological types of locally advanced rectal cancer to neoadjuvant multimodality therapy. J Pak Med Assoc. 2024 Jul; 74(7):1240-1244.

View in: PubMed
Philips R, Sagheer H, Barsouk A, Swendseid B, Johnson J, Bar Ad V, Luginbuhl A, Curry J, Cognetti D. Trends in Adjuvant Therapy After Surgery for Oropharyngeal Squamous Cell Carcinoma. Laryngoscope. 2022 04; 132(4):806-812.

View in: PubMed
Jou J, Charo L, Hom-Tedla M, Coakley K, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer. Gynecol Oncol. 2021 11; 163(2):299-304.

View in: PubMed
Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 02; 26(2):376-386.

View in: PubMed
Carey RM, Brody RM, Shimunov D, Shinn JR, Mady LJ, Rajasekaran K, Cannady SB, Lin A, Lukens JN, Bauml JM, Cohen RB, Basu D, O'Malley BW, Weinstein GS, Newman JG. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS. Laryngoscope. 2021 12; 131(12):E2865-E2873.

View in: PubMed
Issa K, Ackall F, Jung SH, Li J, Jang DW, Rangarajan SV, Abi Hachem R. Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis. Am J Otolaryngol. 2021 Mar-Apr; 42(2):102851.

View in: PubMed
Lutfi W, Martinez-Meehan D, Dhupar R, Christie N, Sarkaria I, Ekeke C, Baker N, Luketich JD, Okusanya OT. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival. J Surg Oncol. 2020 Mar; 121(4):654-661.

View in: PubMed
Gaulin NB, Lesnock JL, Tian C, Osei-Bonsu K, Jacobs A, Richard SD, Krivak TC, Miller EM, Shriver CD, Casablanca Y, Maxwell GL, Darcy KM. Survival disparities in vulvar cancer patients in Commission on Cancer?-accredited facilities. Gynecol Oncol. 2020 04; 157(1):136-145.

View in: PubMed
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020 01; 21(1):145-161.

View in: PubMed
Ecker BL, Vollmer CM, Behrman SW, Allegrini V, Aversa J, Ball CG, Barrows CE, Berger AC, Cagigas MN, Christein JD, Dixon E, Fisher WE, Freedman-Weiss M, Guzman-Pruneda F, Hollis RH, House MG, Kent TS, Kowalsky SJ, Malleo G, Salem RR, Salvia R, Schmidt CR, Seykora TF, Zheng R, Zureikat AH, Dickson PV. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma. JAMA Surg. 2019 08 01; 154(8):706-714.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement